Skip to content
2000
Volume 18, Issue 1
  • ISSN: 2589-9775
  • E-ISSN: 2589-9783

Abstract

Managing Parkinson's Disease (PD) presents formidable challenges due to the impermeability of the Blood-Brain Barrier (BBB), which severely restricts effective drug delivery. Traditional treatment modalities often prove inadequate, prompting the exploration of intranasal drug delivery as a novel and promising alternative. This innovative approach provides direct access to the central nervous system while bypassing the Blood-Brain Barrier (BBB). Recent advancements in nanotechnology, particularly the development of polymeric and lipidic Nanoparticles (NPs), significantly enhance this delivery method by improving mucoadhesion and drug uptake, resulting in elevated drug concentrations in the brain and improved symptomatology. Furthermore, the unique properties of NPs enable sustained drug release, maintaining effective pharmacological levels while minimizing systemic side effects. However, challenges such as potential toxicity, formulation stability, and scalability persist. This review elucidates the role of NPs in surmounting BBB obstacles and underscores the necessity for continued research to optimize their design and ensure long-term safety. As the field advances, intranasal delivery systems hold the promise of becoming pivotal tools in PD management, offering more effective and less invasive therapeutic options for patients.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdrr/10.2174/0125899775352044250519092112
2025-06-25
2026-02-28

  • From This Site

    /content/journals/cdrr/10.2174/0125899775352044250519092112
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. OnofrjM. AjdinajP. DigiovanniA. Functional Neurologic Disorders, disorders to be managed by neurologists, or are neurologists wandering in a dangerous field with inadequate resources?Front. Psychiatry202314112098110.3389/fpsyt.2023.1120981 37009111
     [Google Scholar]
  2. Launch of WHO’s Parkinson disease technical brief.2022Availablefrom: https://www.who.int/news/item/14-06-2022-launch-of-who-s-parkinson-disease-technical-brief
  3. Torres-OrtegaP.V. SaludasL. HanafyA.S. GarbayoE. Blanco-PrietoM.J. Micro- and nanotechnology approaches to improve Parkinson’s disease therapy.J. Control. Release201929520121310.1016/j.jconrel.2018.12.036 30579984
     [Google Scholar]
  4. TolosaE. GarridoA. ScholzS.W. PoeweW. Challenges in the diagnosis of Parkinson’s disease.Lancet Neurol.202120538539710.1016/S1474‑4422(21)00030‑2 33894193
     [Google Scholar]
  5. MarinoB.L.B. de SouzaL.R. SousaK.P.A. Parkinson’s disease: A review from pathophysiology to treatment.Mini Rev. Med. Chem.202020975476710.2174/1389557519666191104110908 31686637
     [Google Scholar]
  6. AgliardiC. GueriniF. MeloniM. ClericiM. Alpha-synuclein as a biomarker in Parkinson’s disease: Focus on neural derived extracelluar vesicles.Neural Regen. Res.20221771503150410.4103/1673‑5374.330604 34916434
     [Google Scholar]
  7. JellingerK.A. A critical evaluation of current staging of α-synuclein pathology in Lewy body disorders.Biochim. Biophys. Acta Mol. Basis Dis.20091792773074010.1016/j.bbadis.2008.07.006 18718530
     [Google Scholar]
  8. NegiS. KhuranaN. DuggalN. The misfolding mystery: α-synuclein and the pathogenesis of Parkinson’s disease.Neurochem. Int.202417710576010.1016/j.neuint.2024.105760 38723900
     [Google Scholar]
  9. PanL. MengL. HeM. ZhangZ. Tau in the pathophysiology of Parkinson’s disease.J. Mol. Neurosci.202171112179219110.1007/s12031‑020‑01776‑5 33459970
     [Google Scholar]
  10. IovinoL. TremblayM.E. CivieroL. Glutamate-induced excitotoxicity in Parkinson’s disease: The role of glial cells.J. Pharmacol. Sci.2020144315116410.1016/j.jphs.2020.07.011 32807662
     [Google Scholar]
  11. BloemB.R. OkunM.S. KleinC. Parkinson’s disease.Lancet2021397102912284230310.1016/S0140‑6736(21)00218‑X 33848468
     [Google Scholar]
  12. WeintraubD. AarslandD. ChaudhuriK.R. The neuropsychiatry of Parkinson’s disease: Advances and challenges.Lancet Neurol.20222118910210.1016/S1474‑4422(21)00330‑6 34942142
     [Google Scholar]
  13. PaulA. YadavK.S. Parkinson’s disease: Current drug therapy and unraveling the prospects of nanoparticles.J. Drug Deliv. Sci. Technol.20205810179010.1016/j.jddst.2020.101790
     [Google Scholar]
  14. SmithY. WichmannT. FactorS.A. DeLongM.R. Parkinson’s disease therapeutics: New developments and challenges since the introduction of levodopa.Neuropsychopharmacology201237121324610.1038/npp.2011.212 21956442
     [Google Scholar]
  15. RathodS. DesaiH. PatilR. SaroliaJ. Non-ionic surfactants as a P-glycoprotein (P-gp) efflux inhibitor for optimal drug delivery—A concise outlook.AAPS PharmSciTech20222315510.1208/s12249‑022‑02211‑1 35043278
     [Google Scholar]
  16. Leyva-GómezG. CortésH. MagañaJ.J. Leyva-GarcíaN. Quintanar-GuerreroD. FloránB. Nanoparticle technology for treatment of Parkinson’s disease: The role of surface phenomena in reaching the brain.Drug Discov. Today201520782483710.1016/j.drudis.2015.02.009 25701281
     [Google Scholar]
  17. BaskinJ. JeonJ.E. LewisS.J.G. Nanoparticles for drug delivery in Parkinson’s disease.J. Neurol.202126851981199410.1007/s00415‑020‑10291‑x 33141248
     [Google Scholar]
  18. WangZ. XiongG. TsangW.C. SchätzleinA.G. UchegbuI.F. Nose-to-brain delivery.J. Pharmacol. Exp. Ther.2019370359360110.1124/jpet.119.258152 31126978
     [Google Scholar]
  19. XinchenY. JingT. JiaoqiongG. Lipid-based nanoparticles via nose-to-brain delivery: A mini review.Front. Cell Dev. Biol.202311121445010.3389/fcell.2023.1214450 37675144
     [Google Scholar]
  20. OmidianH. GillE.J. Dey ChowdhuryS. CubedduL.X. Chitosan nanoparticles for intranasal drug delivery.Pharmaceutics202416674610.3390/pharmaceutics16060746 38931868
     [Google Scholar]
  21. CandelaF. QuartaE. ButtiniF. AnconaA. BettiniR. SonvicoF. Recent patents on nasal vaccines containing nanoadjuvants.Recent Adv. Drug Deliv. Formul.202216210312110.2174/2667387816666220420124648 35450539
     [Google Scholar]
  22. MittalD. AliA. MdS. BabootaS. SahniJ.K. AliJ. Insights into direct nose to brain delivery: Current status and future perspective.Drug Deliv.2014212758610.3109/10717544.2013.838713 24102636
     [Google Scholar]
  23. SharmaS. BatraS. GuptaS. SharmaV.K. RahmanM.H. KamalM.A. Persons with co-existing neurological disorders: Risk analysis, considerations and management in COVID-19 pandemic.CNS Neurol. Disord. Drug Targets202221322823410.2174/1871527320666210308113457 33687889
     [Google Scholar]
  24. IllumL. Transport of drugs from the nasal cavity to the central nervous system.Eur. J. Pharm. Sci.200011111810.1016/S0928‑0987(00)00087‑7 10913748
     [Google Scholar]
  25. PardeshiC. SoutoE.B. Direct Nose-to-Brain Drug Delivery: Mechanism, Technological Advances, Applications, and Regulatory Updates.Academic Press2021
     [Google Scholar]
  26. GhoshA. MajieA. KarmakarV. In-depth mechanism, challenges, and opportunities of delivering therapeutics in brain using intranasal route.AAPS PharmSciTech20242559610.1208/s12249‑024‑02810‑0 38710855
     [Google Scholar]
  27. KhuntD. MisraM. An overview of anatomical and physiological aspects of the nose and the brain.In: Direct Nose-to-Brain Drug Delivery.Cambridge, MassachusettsAcademic Press202131410.1016/B978‑0‑12‑822522‑6.00029‑1
     [Google Scholar]
  28. AlexanderA DwivediS Ajazuddin, et al. Approaches for breaking the barriers of drug permeation through transdermal drug delivery.J. Control. Release20121641264010.1016/j.jconrel.2012.09.017 23064010
     [Google Scholar]
  29. SinghA.K. SinghA. MadhvN.V.S. Nasal cavity, a promising transmucosal platform for drug delivery and research approaches from nasal to brain targetting.J. Drug Deliv. Ther.20122310.22270/jddt.v2i3.163
     [Google Scholar]
  30. BourganisV. KammonaO. AlexopoulosA. KiparissidesC. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics.Eur. J. Pharm. Biopharm.201812833736210.1016/j.ejpb.2018.05.009 29733950
     [Google Scholar]
  31. DhuriaS.V. HansonL.R. FreyW.H. Intranasal delivery to the central nervous system: Mechanisms and experimental considerations.J. Pharm. Sci.20109941654167310.1002/jps.21924 19877171
     [Google Scholar]
  32. LiY. WangC. ZongS. The trigeminal pathway dominates the nose-to-brain transportation of intact polymeric nanoparticles: Evidence from aggregation-caused quenching probes.J. Biomed. Nanotechnol.201915468670210.1166/jbn.2019.2724 30841963
     [Google Scholar]
  33. AkitaT. OdaY. KimuraR. Involvement of trigeminal axons in nose-to-brain delivery of glucagon-like peptide-2 derivative.J. Control. Release202235157358010.1016/j.jconrel.2022.09.047 36179766
     [Google Scholar]
  34. GängerS. SchindowskiK. Tailoring formulations for intranasal nose-to-brain delivery: A review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa.Pharmaceutics201810311610.3390/pharmaceutics10030116 30081536
     [Google Scholar]
  35. PonksheP. ThakkarR.A. MulayT. Nasal and pulmonary drug delivery systems.In: In-Vitro and In-Vivo Tools in Drug Delivery Research for Optimum Clinical Outcomes.Boca Raton, FLCRC Press201879134
     [Google Scholar]
  36. LeeD. MinkoT. Nanotherapeutics for nose-to-brain drug delivery: An approach to bypass the blood brain barrier.Pharmaceutics20211312204910.3390/pharmaceutics13122049 34959331
     [Google Scholar]
  37. FormicaM.L. RealD.A. PicchioM.L. CatlinE. DonnellyR.F. ParedesA.J. On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles.Appl. Mater. Today20222910163110.1016/j.apmt.2022.101631
     [Google Scholar]
  38. JeongS.H. JangJ.H. LeeY.B. Drug delivery to the brain via the nasal route of administration: Exploration of key targets and major consideration factors.J. Pharm. Investig.202353111915210.1007/s40005‑022‑00589‑5 35910081
     [Google Scholar]
  39. PatelA. PatelJ. Inhalable polymeric nano-particulate powders for respiratory delivery.In: Handbook of Lung Targeted Drug Delivery Systems.CRC Press202120922310.1201/9781003046547‑15
     [Google Scholar]
  40. OliveiraP. FortunaA. AlvesG. FalcaoA. Drug-metabolizing enzymes and efflux transporters in nasal epithelium: Influence on the bioavailability of intranasally administered drugs.Curr. Drug Metab.201617762864710.2174/1389200217666160406120509 27048181
     [Google Scholar]
  41. SarkarM.A. Drug metabolism in the nasal mucosa.Pharm. Res.1992911910.1023/A:1018911206646 1589391
     [Google Scholar]
  42. LenzF.A. Ablative surgery for the treatment of Parkinson’s disease.Handbook of Clinical Neurology.Elsevier2007Vol. 84243260
     [Google Scholar]
  43. RabieeN. AhmadiS. AfshariR. Polymeric nanoparticles for nasal drug delivery to the brain: Relevance to Alzheimer’s disease.Adv. Ther.202143200007610.1002/adtp.202000076
     [Google Scholar]
  44. TrevinoJ.T. QuispeR.C. KhanF. NovakV. Non-invasive strategies for nose-to-brain drug delivery.J. Clin. Trials2020107439 33505777
     [Google Scholar]
  45. ChoH.J. BalakrishnanP. LinH. ChoiM.K. KimD.D. Application of biopharmaceutics classification system (BCS) in drug transport studies across human respiratory epithelial cell monolayers.J. Pharm. Investig.201242314715310.1007/s40005‑012‑0020‑9
     [Google Scholar]
  46. RassuG. SorrentiM. CatenacciL. Versatile nasal application of cyclodextrins: Excipients and/or actives?Pharmaceutics2021138118010.3390/pharmaceutics13081180 34452141
     [Google Scholar]
  47. FroelichA. OsmałekT. JadachB. PuriV. Michniak-KohnB. Microemulsion-based media in nose-to-brain drug delivery.Pharmaceutics202113220110.3390/pharmaceutics13020201 33540856
     [Google Scholar]
  48. ComfortC. GarrastazuG. PozzoliM. SonvicoF. Opportunities and challenges for the nasal administration of nanoemulsions.Curr. Top. Med. Chem.201515435636810.2174/1568026615666150108144655 25579345
     [Google Scholar]
  49. JadhavK. GambhireM. ShaikhI. KadamV. PisalS. Nasal drug delivery system-factors affecting and applications.Curr. Drug Ther.200721273810.2174/157488507779422374
     [Google Scholar]
  50. ShimS. YooH.S. The application of mucoadhesive chitosan nanoparticles in nasal drug delivery.Mar. Drugs2020181260510.3390/md18120605 33260406
     [Google Scholar]
  51. NobackM.L. HarvatiK. SpoorF. Climate‐related variation of the human nasal cavity.Am. J. Phys. Anthropol.2011145459961410.1002/ajpa.21523 21660932
     [Google Scholar]
  52. PiresP.C. RodriguesM. AlvesG. SantosA.O. Strategies to improve drug strength in nasal preparations for brain delivery of low aqueous solubility drugs.Pharmaceutics202214358810.3390/pharmaceutics14030588 35335964
     [Google Scholar]
  53. OngW.Y. ShaliniS.M. CostantinoL. Nose-to-brain drug delivery by nanoparticles in the treatment of neurological disorders.Curr. Med. Chem.201421374247425610.2174/0929867321666140716103130 25039773
     [Google Scholar]
  54. GiunchediP. GaviniE. BonferoniM.C. Nose-to-brain delivery.Pharmaceutics202012213810.3390/pharmaceutics12020138 32041344
     [Google Scholar]
  55. AwadR. AvitalA. SosnikA. Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders.Acta Pharm. Sin. B20231351866188610.1016/j.apsb.2022.07.003 37250152
     [Google Scholar]
  56. MdS. BhattmisraS.K. ZeeshanF. Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders.J. Drug Deliv. Sci. Technol.20184329531010.1016/j.jddst.2017.09.022
     [Google Scholar]
  57. EmadN.A. AhmedB. AlhalmiA. AlzobaidiN. Al-KubatiS.S. Recent progress in nanocarriers for direct nose to brain drug delivery.J. Drug Deliv. Sci. Technol.20216410264210.1016/j.jddst.2021.102642
     [Google Scholar]
  58. MistryA. StolnikS. IllumL. Nanoparticles for direct nose-to-brain delivery of drugs.Int. J. Pharm.2009379114615710.1016/j.ijpharm.2009.06.019 19555750
     [Google Scholar]
  59. SalamaM.M. ElzoghbyA.O. Mucoadhesive nanoparticles as promising drug delivery systems.In: Theory and Applications of Nonparenteral Nanomedicines.Elsevier202111313610.1016/B978‑0‑12‑820466‑5.00006‑5
     [Google Scholar]
  60. MorawskiA.S. FachelF.N.S. PohlmannA.R. GuterresS.S. FrankL.A. Polymeric nanoparticles for nose-to-brain delivery in Alzheimer’s and Parkinson’s diseases.In: CNS Drug Development and Delivery: Concepts and Applications.Springer202416317910.1007/978‑3‑031‑62604‑3_7
     [Google Scholar]
  61. KulkarniA.D. VanjariY.H. SanchetiK.H. BelgamwarV.S. SuranaS.J. PardeshiC.V. Nanotechnology-mediated nose to brain drug delivery for Parkinson’s disease: A mini review.J. Drug Target.201523977578810.3109/1061186X.2015.1020809 25758751
     [Google Scholar]
  62. BhattamisraS.K. ShakA.T. XiL.W. Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson’s disease.Int. J. Pharm.202057911914810.1016/j.ijpharm.2020.119148 32084576
     [Google Scholar]
  63. SahaP. SinghP. KathuriaH. ChitkaraD. PandeyM.M. Self-assembled lecithin-chitosan nanoparticles improved rotigotine nose-to-brain delivery and brain targeting efficiency.Pharmaceutics202315385110.3390/pharmaceutics15030851 36986712
     [Google Scholar]
  64. AhmadM.Z. SabriA.H.B. AnjaniQ.K. Domínguez-RoblesJ. Abdul LatipN. HamidK.A. Design and development of levodopa loaded polymeric nanoparticles for intranasal delivery.Pharmaceuticals202215337010.3390/ph15030370 35337167
     [Google Scholar]
  65. TengseK.A. AvariJ.G. DhapkeP. Formulation and evaluation of chitosan nanoparticle based in-situ nasal gel for Parkinson’s disease.World J. Pharm. Res.2020915859880
     [Google Scholar]
  66. MdS. AlhakamyN.A. AldawsariH.M. AsfourH.Z. Neuroprotective and antioxidant effect of naringenin-loaded nanoparticles for nose-to-brain delivery.Brain Sci.201991027510.3390/brainsci9100275 31618942
     [Google Scholar]
  67. RajR. WairkarS. SridharV. GaudR. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity.Int. J. Biol. Macromol.2018109273510.1016/j.ijbiomac.2017.12.056 29247729
     [Google Scholar]
  68. RukmangathenR. YallamalliI.M. YalavarthiP.R. Biopharmaceutical potential of selegiline loaded chitosan nanoparticles in the management of Parkinson’s disease.Curr. Drug Discov. Technol.201916441742510.2174/1570163815666180418144019 29669501
     [Google Scholar]
  69. SharmaD. SharmaR.K. SharmaN. Nose-to-brain delivery of PLGA-Diazepam nanoparticles.AAPS PharmSciTech20151651108112110.1208/s12249‑015‑0294‑0 25698083
     [Google Scholar]
  70. MusumeciT. SerapideM.F. PellitteriR. Oxcarbazepine free or loaded PLGA nanoparticles as effective intranasal approach to control epileptic seizures in rodents.Eur. J. Pharm. Biopharm.201813330932010.1016/j.ejpb.2018.11.002 30399400
     [Google Scholar]
  71. RawalS.U. PatelB.M. PatelM.M. New drug delivery systems developed for brain targeting.Drugs202282774979210.1007/s40265‑022‑01717‑z 35596879
     [Google Scholar]
  72. ArisoyS. SayinerO. ComogluT. OnalD. AtalayO. PehlivanogluB. In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery.Pharm. Dev. Technol.202025673574710.1080/10837450.2020.1740257 32141798
     [Google Scholar]
  73. NigamK. KaurA. TyagiA. Nose-to-brain delivery of lamotrigine-loaded PLGA nanoparticles.Drug Deliv. Transl. Res.20199587989010.1007/s13346‑019‑00622‑5 30887226
     [Google Scholar]
  74. ShahP. DubeyP. VyasB. Lamotrigine loaded PLGA nanoparticles intended for direct nose to brain delivery in epilepsy: Pharmacokinetic, pharmacodynamic and scintigraphy study.Artif. Cells Nanomed. Biotechnol.202149151152210.1080/21691401.2021.1939709 34151674
     [Google Scholar]
  75. TangS. WangA. YanX. Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson’s disease.Drug Deliv.201926170070710.1080/10717544.2019.1636420 31290705
     [Google Scholar]
  76. BiC. WangA. ChuY. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment.Int. J. Nanomedicine2016116547655910.2147/IJN.S120939 27994458
     [Google Scholar]
  77. WenZ. YanZ. HuK. Odorranalectin-conjugated nanoparticles: Preparation, brain delivery and pharmacodynamic study on Parkinson’s disease following intranasal administration.J. Control. Release2011151213113810.1016/j.jconrel.2011.02.022 21362449
     [Google Scholar]
  78. ChatzitakiA.T. JesusS. KaravasiliC. AndreadisD. FatourosD.G. BorgesO. Chitosan-coated PLGA nanoparticles for the nasal delivery of ropinirole hydrochloride: In vitro and ex vivo evaluation of efficacy and safety.Int. J. Pharm.202058911977610.1016/j.ijpharm.2020.119776 32818538
     [Google Scholar]
  79. WilsonB. SamantaM.K. SanthiK. KumarK.P.S. ParamakrishnanN. SureshB. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s disease.Brain Res.2008120015916810.1016/j.brainres.2008.01.039 18291351
     [Google Scholar]
  80. BoyuklievaR. HristozovaA. PilichevaB. Synthesis and characterization of PCL-Idebenone nanoparticles for potential nose-to-brain delivery.Biomedicines2023115149110.3390/biomedicines11051491 37239161
     [Google Scholar]
  81. BadranM.M. AlanaziA.E. IbrahimM.A. AlshoraD.H. TahaE. H AlomraniA. Optimization of bromocriptine-mesylate-loaded polycaprolactone nanoparticles coated with chitosan for nose-to-brain delivery: In vitro and in vivo studies.Polymers20231519389010.3390/polym15193890 37835942
     [Google Scholar]
  82. DarwishW.M. BayoumiN.A. EbeidN.H. Biocompatible mucoadhesive nanoparticles for brain targeting of ropinirole hydrochloride: Formulations, radiolabeling and biodistribution.Biopolymers20221136e2348910.1002/bip.23489 35403210
     [Google Scholar]
  83. FigueirasA. DominguesC. JarakI. New advances in biomedical application of polymeric micelles.Pharmaceutics2022148170010.3390/pharmaceutics14081700 36015325
     [Google Scholar]
  84. KottaS. AldawsariH.M. Badr-EldinS.M. NairA.B. YtK. Progress in polymeric micelles for drug delivery applications.Pharmaceutics2022148163610.3390/pharmaceutics14081636 36015262
     [Google Scholar]
  85. WangF. YangZ. LiuM. Facile nose-to-brain delivery of rotigotine-loaded polymer micelles thermosensitive hydrogels: In vitro characterization and in vivo behavior study.Int. J. Pharm.202057711904610.1016/j.ijpharm.2020.119046 31982559
     [Google Scholar]
  86. ZhangL. YangS. HuangL. HoP.C.L. Poly (ethylene glycol)-block-poly (D, L-lactide) (PEG-PLA) micelles for brain delivery of baicalein through nasal route for potential treatment of neurodegenerative diseases due to oxidative stress and inflammation: An in vitro and in vivo study.Int. J. Pharm.202059111998110.1016/j.ijpharm.2020.119981 33069896
     [Google Scholar]
  87. YoonG. ParkJ.W. YoonI.S. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): Recent advances in drug delivery.J. Pharm. Investig.201343535336210.1007/s40005‑013‑0087‑y
     [Google Scholar]
  88. HaftcheshmehS.M. JaafariM.R. MashreghiM. Liposomal doxorubicin targeting mitochondria: A novel formulation to enhance anti-tumor effects of Doxil® in vitro and in vivo.J. Drug Deliv. Sci. Technol.20216210235110.1016/j.jddst.2021.102351
     [Google Scholar]
  89. PuriA. LoomisK. SmithB. Lipid-based nanoparticles as pharmaceutical drug carriers: From concepts to clinic.Crit. Rev. Ther. Drug Carrier Syst.200926652358010.1615/CritRevTherDrugCarrierSyst.v26.i6.10 20402623
     [Google Scholar]
  90. PandianS.R.K. VijayakumarK.K. MurugesanS. KunjiappanS. Liposomes: An emerging carrier for targeting Alzheimer’s and Parkinson’s diseases.Heliyon202286e0957510.1016/j.heliyon.2022.e09575 35706935
     [Google Scholar]
  91. KhotK.B. Enhancing selegiline hydrochloride efficacy: Box Behnken-optimized liposomal delivery via intranasal route for Parkinson’s disease intervention.J. Liposome Res.202434457559210.1080/08982104.2024.2336549 38591935
     [Google Scholar]
  92. AnsariM.S. AliA. RashidM.A. BBD assisted in-situ nanoliposomes of esculin hydrate via intranasal delivery for the amelioration of Parkinson’s disease.J. Drug Deliv. Sci. Technol.20249610565810.1016/j.jddst.2024.105658
     [Google Scholar]
  93. AhmedM.R. InayathullahM. MortonM. Intranasal delivery of liposome encapsulated flavonoids ameliorates l-DOPA induced dyskinesia in hemiparkinsonian mice.Biomaterials202431112268010.1016/j.biomaterials.2024.122680 38959534
     [Google Scholar]
  94. PittaS.K. DudhipalaN. NaralaA. VeerabrahmaK. Development of zolmitriptan transfersomes by Box–Behnken design for nasal delivery: In vitro and in vivo evaluation.Drug Dev. Ind. Pharm.201844348449210.1080/03639045.2017.1402918 29124986
     [Google Scholar]
  95. Fernández-GarcíaR. LalatsaA. StattsL. Bolás-FernándezF. BallesterosM.P. SerranoD.R. Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale.Int. J. Pharm.202057311881710.1016/j.ijpharm.2019.118817 31678520
     [Google Scholar]
  96. ElShageaH.N. MakarR.R. SalamaA.H. ElkasabgyN.A. BasaliousE.B. Investigating the targeting power to brain tissues of intranasal rasagiline mesylate-loaded transferosomal in situ gel for efficient treatment of Parkinson’s disease.Pharmaceutics202315253310.3390/pharmaceutics15020533 36839855
     [Google Scholar]
  97. SalemH.F. KharshoumR.M. Abou-TalebH.A. NaguibD.M. Nanosized transferosome-based intranasal in situ gel for brain targeting of resveratrol: Formulation, optimization, in vitro evaluation, and in vivo pharmacokinetic study.AAPS PharmSciTech201920518110.1208/s12249‑019‑1353‑8 31049748
     [Google Scholar]
  98. ShuklaR. KumarA. FloraS.J.S. Nanotechnological advances in direct nose-to-brain drug delivery for neurodegenerative disorders and other neuroailments.Direct Nose-to-Brain Drug Delivery. PardeshiC.V. SoutoE.B. Academic Press2021739110.1016/B978‑0‑12‑822522‑6.00005‑9
     [Google Scholar]
  99. MishraN. TiwariD.K. MishraK. GuptaA. SumanS. MishraS. Development of intranasal deformable ethosomes of rasagiline mesylate for the effective management of parkinsonism.Int. J. Pharm. Biol. Sci.2020102533
     [Google Scholar]
  100. BattagliaL. PancianiP.P. MuntoniE. Lipid nanoparticles for intranasal administration: Application to nose-to-brain delivery.Expert Opin. Drug Deliv.201815436937810.1080/17425247.2018.1429401 29338427
     [Google Scholar]
  101. YasirM. Vir Singh SaraU. SomI. GaurP. SinghM. Nose to brain drug delivery: A novel approach through solid lipid nanoparticles.Curr. Nanomed.20166212110.2174/246818730666616060312
     [Google Scholar]
  102. UppuluriC.T. RaviP.R. DalviA.V. Design, optimization and pharmacokinetic evaluation of Piribedil loaded solid lipid nanoparticles dispersed in nasal in situ gelling system for effective management of Parkinson’s disease.Int. J. Pharm.202160612088110.1016/j.ijpharm.2021.120881 34273426
     [Google Scholar]
  103. PrajapatiJ.B. PatelG.C. Nose to brain delivery of Rotigotine loaded solid lipid nanoparticles: Quality by design based optimization and characterization.J. Drug Deliv. Sci. Technol.20216310237710.1016/j.jddst.2021.102377
     [Google Scholar]
  104. TrapaniA. CastellaniS. GuerraL. Combined dopamine and grape seed extract-loaded solid lipid nanoparticles: Nasal mucosa permeation, and uptake by olfactory ensheathing cells and neuronal SH-SY5Y cells.Pharmaceutics202315388110.3390/pharmaceutics15030881 36986742
     [Google Scholar]
  105. MüllerR.H. AlexievU. SinambelaP. KeckC.M. Nanostructured Lipid Carriers (NLC): The Second Generation of Solid Lipid Nanoparticles.Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement: Nanocarriers. DragicevicN. MaibachH.I. Berlin, HeidelbergSpringer201616118510.1007/978‑3‑662‑47862‑2_11
     [Google Scholar]
  106. IqbalM.A. MdS. SahniJ.K. BabootaS. DangS. AliJ. Nanostructured lipid carriers system: Recent advances in drug delivery.J. Drug Target.2012201081383010.3109/1061186X.2012.716845 22931500
     [Google Scholar]
  107. CunhaS. ForbesB. LoboSousa Improving drug delivery for Alzheimer’s disease through nose-to-brain delivery using nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ hydrogels.Int. J. Nanomedicine2021164373439010.2147/IJN.S305851 34234432
     [Google Scholar]
  108. NehaS.L. MishraA.K. RaniL. ParohaS. DewanganH.K. SahooP.K. Design and evaluations of a nanostructured lipid carrier loaded with dopamine hydrochloride for intranasal bypass drug delivery in Parkinson’s disease.J. Microencapsul.202340859961210.1080/02652048.2023.2264386 37787159
     [Google Scholar]
  109. GartziandiaO. HerránE. Ruiz-OrtegaJ.A. Intranasal administration of chitosan-coated nanostructured lipid carriers loaded with GDNF improves behavioral and histological recovery in a partial lesion model of Parkinson’s disease.J. Biomed. Nanotechnol.201612122220228010.1166/jbn.2016.2313 29372975
     [Google Scholar]
  110. BenderT.S. MiglioreM.M. CampbellR.B. John GatleyS. WaszczakB.L. Intranasal administration of glial-derived neurotrophic factor (GDNF) rapidly and significantly increases whole-brain GDNF level in rats.Neuroscience201530356957610.1016/j.neuroscience.2015.07.016 26166725
     [Google Scholar]
  111. AllegrittiE. BattistaS. MaggiM.A. MarconiC. GalantiniL. GiansantiL. Novel liposomal formulations for protection and delivery of levodopa: Structure-properties correlation.Int. J. Pharm.202364312323010.1016/j.ijpharm.2023.123230 37454830
     [Google Scholar]
  112. PardeshiC.V. RajputP.V. BelgamwarV.S. TekadeA.R. SuranaS.J. Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: Application of factorial design approach.Drug Deliv.2013201475610.3109/10717544.2012.752421 23311653
     [Google Scholar]
  113. Chandra BhattP. SrivastavaP. PandeyP. KhanW. PandaB.P. Nose to brain delivery of astaxanthin-loaded solid lipid nanoparticles: Fabrication, radio labeling, optimization and biological studies.RSC Advances2016612100011001010.1039/C5RA19113K
     [Google Scholar]
  114. Megala ManiS.B. KishoreR. Neuroprotective potential of Naringenin-loaded solid-lipid nanoparticles against rotenone-induced Parkinson’s disease model.J. Appl. Pharm. Sci.2021112192810.7324/JAPS.2021.110203
     [Google Scholar]
  115. HassanD.M. El-KamelA.H. AllamE.A. BakrB.A. AshourA.A. Chitosan-coated nanostructured lipid carriers for effective brain delivery of Tanshinone IIA in Parkinson’s disease: Interplay between nuclear factor-kappa β and cathepsin B.Drug Deliv. Transl. Res.202414240041710.1007/s13346‑023‑01407‑7 37598133
     [Google Scholar]
  116. MishraN. SharmaS. DeshmukhR. KumarA. SharmaR. Development and characterization of nasal delivery of selegiline hydrochloride loaded nanolipid carriers for the management of Parkinson’s disease.Cent. Nerv. Syst. Agents Med. Chem.2019191465610.2174/1871524919666181126124846 30474538
     [Google Scholar]
  117. HernandoS. HerranE. Figueiro-SilvaJ. Intranasal administration of TAT-conjugated lipid nanocarriers loading GDNF for Parkinson’s disease.Mol. Neurobiol.201855114515510.1007/s12035‑017‑0728‑7 28866799
     [Google Scholar]
  118. ZafarA. Awad AlsaidanO. AlruwailiN.K. Formulation of intranasal surface engineered nanostructured lipid carriers of rotigotine: Full factorial design optimization, in vitro characterization, and pharmacokinetic evaluation.Int. J. Pharm.202262712223210.1016/j.ijpharm.2022.122232 36155794
     [Google Scholar]
  119. ElkomyM.H. ZakiR.M. AlsaidanO.A. Intranasal nanotransferosomal gel for quercetin brain targeting: I. optimization, characterization, brain localization, and cytotoxic studies.Pharmaceutics2023157180510.3390/pharmaceutics15071805 37513991
     [Google Scholar]
  120. MustafaG. AhujaA. AliJ. Nose to brain targeting potential of a chitosancoated nano-formulation: Pharmacodynamic and pharmacoscintigraphic evaluation.Sci. Adv. Mater.2013591236124910.1166/sam.2013.1578
     [Google Scholar]
  121. GabaB. KhanT. HaiderM.F. Vitamin E loaded naringenin nanoemulsion via intranasal delivery for the management of oxidative stress in a 6-OHDA Parkinson’s disease model.BioMed Res. Int.20192019112010.1155/2019/2382563 31111044
     [Google Scholar]
  122. PangeniR. SharmaS. MustafaG. AliJ. BabootaS. Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson’s disease by reducing oxidative stress.Nanotechnology2014254848510210.1088/0957‑4484/25/48/485102 25392203
     [Google Scholar]
  123. Usama AshharM. VyasP. VohoraD. Amelioration of oxidative stress utilizing nanoemulsion loaded with bromocriptine and glutathione for the management of Parkinson’s disease.Int. J. Pharm.202261812168310.1016/j.ijpharm.2022.121683 35314276
     [Google Scholar]
  124. KhatriD.K. PreetiK. TonapeS. Nanotechnological advances for nose to brain delivery of therapeutics to improve the Parkinson therapy.Curr. Neuropharmacol.202321349351610.2174/1570159X20666220507022701 35524671
     [Google Scholar]
  125. BonferoniM.C. RossiS. SandriG. Nanoemulsions for “nose-to-brain” drug delivery.Pharmaceutics20191128410.3390/pharmaceutics11020084 30781585
     [Google Scholar]
  126. BoyuklievaR. PilichevaB. Micro- and nanosized carriers for nose-to-brain drug delivery in neurodegenerative disorders.Biomedicines2022107170610.3390/biomedicines10071706 35885011
     [Google Scholar]
  127. KumarS. AliJ. BabootaS. Design Expert ® supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson’s disease.Nanotechnology2016274343510110.1088/0957‑4484/27/43/435101 27655136
     [Google Scholar]
  128. MisraS.K. PathakK. Nose-to-brain targeting via nanoemulsion: Significance and evidence.Colloids and Interfaces2023712310.3390/colloids7010023
     [Google Scholar]
  129. NehalN. NabiB. RehmanS. Chitosan coated synergistically engineered nanoemulsion of Ropinirole and nigella oil in the management of Parkinson’s disease: Formulation perspective and in vitro and in vivo assessment.Int. J. Biol. Macromol.202116760561910.1016/j.ijbiomac.2020.11.207 33278450
     [Google Scholar]
  130. ChoudhuryH. ZakariaN.F.B. TilangP.A.B. Formulation development and evaluation of rotigotine mucoadhesive nanoemulsion for intranasal delivery.J. Drug Deliv. Sci. Technol.20195410130110.1016/j.jddst.2019.101301
     [Google Scholar]
  131. Al-JipouriA. EritjaÀ. BozicM. Unraveling the multifaceted roles of extracellular vesicles: Insights into biology, pharmacology, and pharmaceutical applications for drug delivery.Int. J. Mol. Sci.202325148510.3390/ijms25010485 38203656
     [Google Scholar]
  132. MaachaS. BhatA.A. JimenezL. Extracellular vesicles-mediated intercellular communication: Roles in the tumor microenvironment and anti-cancer drug resistance.Mol. Cancer20191815510.1186/s12943‑019‑0965‑7 30925923
     [Google Scholar]
  133. ClaridgeB. LozanoJ. PohQ.H. GreeningD.W. Development of extracellular vesicle therapeutics: Challenges, considerations, and opportunities.Front. Cell Dev. Biol.2021973472010.3389/fcell.2021.734720 34616741
     [Google Scholar]
  134. RichterM. VaderP. FuhrmannG. Approaches to surface engineering of extracellular vesicles.Adv. Drug Deliv. Rev.202117341642610.1016/j.addr.2021.03.020 33831479
     [Google Scholar]
  135. TieuA. Extracellular Vesicles Derived from Mesenchymal Stromal Cells: A Multidisciplinary Analysis of Methodology, Efficacy and Biodistribution in Lung Disease.Université d'Ottawa/University of Ottawa2023
     [Google Scholar]
  136. WangS. KongH. ZhuoC. Functionalized extracellular nanovesicles as advanced CRISPR delivery systems.Biomater. Sci.202412143480349910.1039/D4BM00054D 38808607
     [Google Scholar]
  137. TikhonovA. KachanovA. YudaevaA. Biomimetic nanoparticles for basic drug delivery.Pharmaceutics20241610130610.3390/pharmaceutics16101306 39458635
     [Google Scholar]
  138. ChenY. WeiC. LyuY. ChenH. JiangG. GaoX. Biomimetic drug-delivery systems for the management of brain diseases.Biomater. Sci.2020841073108810.1039/C9BM01395D 31728485
     [Google Scholar]
  139. LiuY. LuoJ. LiuY. Brain-targeted biomimetic nanodecoys with neuroprotective effects for precise therapy of Parkinson’s disease.ACS Cent. Sci.2022891336134910.1021/acscentsci.2c00741 36188350
     [Google Scholar]
  140. GandhiS. ShastriD.H. ShahJ. NairA.B. JacobS. Nasal delivery to the brain: Harnessing nanoparticles for effective drug transport.Pharmaceutics202416448110.3390/pharmaceutics16040481 38675142
     [Google Scholar]
  141. PaulW. SharmaC. P. Inorganic nanoparticles for targeted drug delivery.In: Biointegration of Medical Implant Materials.Woodhead Publishing2020333373
     [Google Scholar]
  142. UnnikrishnanG. JoyA. MeghaM. KolanthaiE. SenthilkumarM. Exploration of inorganic nanoparticles for revolutionary drug delivery applications: A critical review.Discov. Nano202318115710.1186/s11671‑023‑03943‑0 38112849
     [Google Scholar]
  143. de BarrosC PortugalI BatainF Formulation, design and strategies for efficient nanotechnology-based nasal delivery systems.202211rqac00310.1093/rpsppr/rqac003
     [Google Scholar]
  144. InbarajB.S. ChenB-H. An overview on recent in vivo biological application of cerium oxide nanoparticles.Asian J. Pharm. Sci.202015555857510.1016/j.ajps.2019.10.005 33193860
     [Google Scholar]
  145. ChenB.H. Stephen InbarajB. Various physicochemical and surface properties controlling the bioactivity of cerium oxide nanoparticles.Crit. Rev. Biotechnol.20183871003102410.1080/07388551.2018.1426555 29402135
     [Google Scholar]
  146. Mohammad, Khan UA, Saifi Z, et al. Intranasal inorganic cerium oxide nanoparticles ameliorate oxidative stress induced motor manifestations in haloperidol-induced parkinsonism. Inflammopharmacology202331525718510.1007/s10787‑023‑01274‑1 37432554
     [Google Scholar]
  147. KulkarniV. ShawC. Formulation and characterization of nasal sprays. An examination of nasal spray formulation parameters and excipients and their influence on key in vitro tests.Inhalation20121015
     [Google Scholar]
  148. BhattM. BhattG.K. An overview: Formulation and product development of nasal spray.World J. Pharm. Res.2017640441310.20959/wjpr20176‑8557
     [Google Scholar]
  149. XiaX. ZhongZ. WeiC. Lyotropic liquid crystalline based nasal spray for improved Parkinson’s treatment: Enhanced superior nasal tract deposition and antioxidation strategy.Adv. Funct. Mater.2025351241142610.1002/adfm.202411426
     [Google Scholar]
/content/journals/cdrr/10.2174/0125899775352044250519092112
Loading
Nanotherapeutics Mediated Intranasal Delivery for Therapeutic Effect on Parkinson’s Disease: Balancing Advancements and Challenges
Current Drug Research Reviews 18, 16 (2026); https://doi.org/10.2174/0125899775352044250519092112
/content/journals/cdrr/10.2174/0125899775352044250519092112
/content/journals/cdrr/10.2174/0125899775352044250519092112
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): blood-brain barrier; intranasal delivery; lipidic nanoparticles; nanoparticles; nose-to-brain delivery; Parkinson’s disease; polymeric nanoparticles

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test